Fredag 7 November | 10:47:07 Europe / Stockholm

Kalender

Est. tid*
2026-02-05 08:30 Bokslutskommuniké 2025
2025-11-13 08:30 Kvartalsrapport 2025-Q3
2025-08-21 - Kvartalsrapport 2025-Q2
2025-05-30 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2025-05-28 - Årsstämma
2025-05-15 - Kvartalsrapport 2025-Q1
2025-02-06 - Bokslutskommuniké 2024
2024-11-14 - Kvartalsrapport 2024-Q3
2024-10-30 - Split EXPRS2 40:1
2024-08-15 - Kvartalsrapport 2024-Q2
2024-06-07 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2024-06-05 - Årsstämma
2024-05-16 - Kvartalsrapport 2024-Q1
2024-02-08 - Bokslutskommuniké 2023
2023-11-16 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-05-25 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2023-05-24 - Årsstämma
2023-05-16 - Kvartalsrapport 2023-Q1
2023-03-23 - Extra Bolagsstämma 2023
2023-02-09 - Bokslutskommuniké 2022
2022-11-17 - Kvartalsrapport 2022-Q3
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-31 - Kvartalsrapport 2022-Q1
2022-05-27 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2022-05-25 - Årsstämma
2022-02-24 - Bokslutskommuniké 2021
2021-11-18 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-27 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2021-05-26 - Årsstämma
2021-05-19 - Kvartalsrapport 2021-Q1
2021-02-25 - Bokslutskommuniké 2020
2020-11-19 - Kvartalsrapport 2020-Q3
2020-09-23 - Extra Bolagsstämma 2020
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-27 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2020-05-26 - Årsstämma
2020-05-20 - Kvartalsrapport 2020-Q1
2020-02-28 - Bokslutskommuniké 2019
2019-11-14 - Kvartalsrapport 2019-Q3
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-24 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2019-05-23 - Årsstämma
2019-05-16 - Kvartalsrapport 2019-Q1
2019-02-28 - Bokslutskommuniké 2018
2018-11-22 - Kvartalsrapport 2018-Q3
2018-08-24 - Kvartalsrapport 2018-Q2
2018-05-25 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2018-05-24 - Årsstämma
2018-05-17 - Kvartalsrapport 2018-Q1
2018-02-07 - Bokslutskommuniké 2017
2017-11-30 - Kvartalsrapport 2017-Q3
2017-08-31 - Kvartalsrapport 2017-Q2
2017-06-01 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2017-05-31 - Årsstämma
2017-05-24 - Kvartalsrapport 2017-Q1
2017-04-19 - Extra Bolagsstämma 2017
2017-02-28 - Bokslutskommuniké 2016
2016-11-08 - Kvartalsrapport 2016-Q3
2016-08-31 - Kvartalsrapport 2016-Q2

Beskrivning

LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
ExpreS2ion är ett bioteknikbolag fokuserat på utveckling av vacciner. Bolagets mål att bidra till hälso- och sjukvården genom att utveckla vacciner ämnade att stödja sjukdomsförebyggande och förbättra livskvaliteten globalt. ExpreS2ion använder sin ExpreS2™-teknologiplattform, som har validerats i kliniska fas III-studier, för utveckling och produktion av vaccinkomponenter. Bland pågående projekt utvecklar bolaget ES2B-C001, ett HER2-cVLP bröstcancervaccin som genomgår kliniska fas I-prövningar.
2024-11-20 08:30:00
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, RUSSIA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm, Denmark, 20 November 2024 - ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") announces that today begins the exercise period for the warrants of series TO 10, which were issued in connection with the Company's rights issues of units announced on 2 May 2024. Note that warrants of series TO 10 not sold by 2 December 2024, or alternatively used to subscribe for shares no later than on 4 December 2024, expire without value.

ExpreS2ion completed a rights issue of units during the third quarter of 2024. Within the scope of the rights issue, ExpreS2ion issued 30,046,672 warrants of series TO 10. Furthermore, ExpreS2ion issued an additional 2,175,000 warrants of series TO 10 to guarantors in the rights issue who chose to receive guarantee compensation in units.

Prior to recalculation of the warrants of series TO 10, one (1) warrant of series TO 10 gave the owner the right to subscribe for one (1) new share in the Company. Following the recalculation of the warrants, which is explained in more detail below, forty (40) warrants of series TO 10 gives the owner the right to subscribe for one (1) new share in the Company. The exercise price for the warrants of series TO 10 was defined as 70 percent of the volume-weighted average price in the Company's share on Nasdaq First North Growth Market during the measurement period, from 1 November 2024 to 14 November 2024, but not less than the share's quota value (SEK 4.444444) (previously SEK 0.111111) and not more than SEK 60 (previously SEK 1.5) per share after recalculation. During the measurement period, the volume-weighted average price in the Company's share was approximately SEK 25.59, therefore the exercise price for the warrants of series TO 10 has been set to SEK 17.91. The exercise period for warrants of series TO 10 runs from 20 November 2024 up to and including 4 December 2024.

If all the warrants of series TO 10 are exercised, the Company will receive approximately SEK 14.4 million before issuing costs. For the warrants to not expire without value, it is required that the holder actively subscribes for new shares no later than on 4 December 2024 or sell the warrants no later than on 2 December 2024. Please observe that certain nominees might close their applications earlier than on 4 December 2024.

Full terms and conditions regarding the warrants of series TO 10 and information about the Company is available in the prospectus which was approved by the Swedish Financial Supervisory Authority (the "SFSA") and published by the Company on 5 June 2024. The prospectus is available on the Company's investor relations website investor.expres2ionbio.com, as well as the SFSA's website www.fi.se.

Summarised terms for the warrants of series TO 10

  • Exercise period: 20 November 2024 - 4 December 2024.
  • Issue size: 32,221,672 warrants of series TO 10, which entitles to subscription of 805,541 shares. If all the warrants are exercised, the Company will receive approximately SEK 14.4 million before issuing costs.
  • Forty (40) warrants of series TO 10 will be required to subscribe for one (1) new share in the Company.
  • Exercise price: SEK 17.91 per share.
  • Last day for trading warrants of series TO 10: 2 December 2024.
  • Dilution: If all warrants are exercised the share capital will increase with SEK 3,580,182.228718. If all warrants of series TO 10 are exercised the number of shares will increase with 805,541 shares. The dilution if all warrants of series TO 10 are exercised amounts to approximately 27.7 percent of the number of shares and votes in the Company.

Note that the warrants that are not exercised on 4 December 2024 at the latest or sold no later than on 2 December 2024, will expire without value. For the warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants.

How warrants are exercised

Nominee-registered warrants (Custody account) - Subscription and payment by the exercise of warrants shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information. This should be done well before 4 December 2024, as different nominees have different processing times.

Directly-registered warrants (Securities account) - No issue report nor any instructions regarding payments will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form.

The warrants will then be replaced by interim shares awaiting registration at the Swedish Companies Registration Office.

Additional information, including the TO 10 Subscription Brochure and the application form with payment instructions, is available in the Rights Issue 2024 section on ExpreS2ion's investor website (https://investor.expres2ionbio.com/rights-issue-2024/). The application form will also be made available on Vator Securities website (www.vatorsecurities.se).

Advisors
Vator Securities act as financial advisor and issuing agent to the Company in connection with the transaction. Advokatfirman Schjødt is the Company's legal advisor in connection with the transaction.

Certified Advisor
Svensk Kapitalmarknadsgranskning AB